학술논문

Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines
Document Type
Journal
Source
CANCER RESEARCH; MAR 1 2023, 83 5, 3p. Supplement: S
Subject
Language
English
ISSN
15387445